Citations

Showing 10 of 108119 citations.

Early Warning Signs and Rapid Response on the Nursing Floor—Can We Do More?
Sims, Charles R. , Elmer, Jennifer, Jensen, Jeffrey B., Sims, Charles Chase R

Mayo Clinic

International Anesthesiology Clinics | March 13, 2019 | Volume: 57 | Issue: 2 | Pages: 61-74

10.1097/aia.0000000000000228 | PMID 30864991 Get It

Critical Care Echocardiography—Embracing the Future Today
Hernandez-Torres, Vivian , Prada, Gabriel , Díaz‐Gómez, José L. , Díaz-Gómez, José L

Mayo Clinic

International Anesthesiology Clinics | March 13, 2019 | Volume: 57 | Issue: 2 | Pages: 75-88

10.1097/aia.0000000000000225 | PMID 30864992 Get It

Prevention and Management of the Critically Injured Kidney
Shawwa, Khaled , Kashani, Kianoush

Mayo Clinic

International Anesthesiology Clinics | March 13, 2019 | Volume: 57 | Issue: 2 | Pages: 48-60

10.1097/aia.0000000000000224 | PMID 30864990 Get It

Correction to: Anterior cruciate ligament reconstruction with concomitant meniscal surgery: a systematic review and meta‐analysis of outcomes
Sarraj, Mohamed , Coughlin, Ryan P., Solow, Max, Simunovic, Nicole , Krych, Aaron J. , MacDonald, Peter B. , Ayeni, Olufemi R. , Ayeni, Olufemi R , Krych, Aaron J , Coughlin, Ryan P., Ekhtiari, Seper

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | March 13, 2019 | Volume: 27 | Issue: 11 | Pages: 3453-3453

10.1007/s00167-019-05409-2 | PMID 30868187 Get It

Unfortunately, the middle name of Olufemi R. Ayeni was accidentally omitted in the original publication and the author name is corrected here. The original article has been corrected.
PREVAPIX-ALL: Apixaban Compared to Standard of Care for Prevention of Venous Thrombosis in Paediatric Acute Lymphoblastic Leukaemia (ALL)—Rationale and Design
O’Brien, Sarah H. , Li, Danshi, Mitchell, Lesley , Zee, Pamela, Yee, Donald L., Sung, Lillian , Rodriguez, Vilmarie , Hess, Thomas A. , Newburger, Jane W.

Mayo Clinic

Thrombosis and Haemostasis | March 12, 2019 | Volume: 119 | Issue: 05 | Pages: 844-853

10.1055/s-0039-1679938 | PMID 30861550 Get It

AbstractVenous thromboembolic (VTE) complications in children and adolescents with acute lymphoblastic leukaemia (ALL) and T or B cell lymphoblastic lymphoma (T/B cell LL) can result not only in life-threatening acute complications but also contribute to significant long-term sequelae. The PREVAPIX-ALL study is an open-label randomized controlled study comparing outcomes of treatment with prophylactic dose apixaban versus no anticoagulation (standard of care) in children and adolescents with ALL and T/B cell LL receiving standard induction chemotherapy with asparaginase and the presence of a central venous access device. On day 29 of induction, all patients undergo screening imaging with duplex ultrasonography and echocardiography. The primary efficacy endpoint of the study is a composite of symptomatic and asymptomatic VTE that includes deep vein thrombosis, pulmonary embolism, cerebral sinovenous thrombosis or VTE-related death. The primary safety outcome is major bleeding. Secondary outcomes are central line-associated infections, patency and line replacement, superficial thrombosis, arterial events and death. A planned sample size of 500 randomized paediatric patients enrolled over a period of 5 years is based on the estimation of VTE rates of 20 and 10% in the standard of care and apixaban groups, respectively. An optional biomarker study in 150 patients will examine predictors of increased VTE risk and study in vivo anticoagulant effects of apixaban in children by measuring specific biomarkers in the haemostatic system and inflammatory pathway. This study will provide valuable information for the safety and efficacy of apixaban in VTE prevention during induction in paediatric ALL.
Reference Intervals for Thyroid Hormones During the First Trimester of Gestation: A Report from an Area with a Sufficient Iodine Level
Kianpour, Maryam , Aminorroaya, Ashraf , Amini, Masoud , Feizi, Awat , Janghorbani, Mohsen , Shokri, Saeideh, Yamini, Sima Aminorroaya , Farghadani, Maryam , Hekmatnia, Ali , Gharib, Hossien

Mayo Clinic

Hormone and Metabolic Research | March 12, 2019 | Volume: 51 | Issue: 03 | Pages: 165-171

10.1055/a-0855-7128 | PMID 30861562 Get It

AbstractThe physiological changes during pregnancy modulate the endocrine system. Therefore, both the American and the European thyroid associations recommend the use of local trimester-specific reference intervals. The purpose of this study was to establish the first trimester reference intervals for thyroid function tests in the central area of Iran. We examined 436 pregnant women in their first trimester of pregnancy, and 444 non-pregnant women in a cross sectional study. Serum levels of thyroid stimulating hormone (TSH), free thyroxin (FT4), free triiodothyronine (FT3), thyroid peroxidase antibody, urinary iodine concentration (UIC), and thyroid volume were measured for all subjects. The first trimester-specific reference intervals (2.5th–97.5th percentile) were determined for 185 pregnant women and 256 non-pregnant women with negative TPOAb, adequate iodine level (UIC≥150 μg/l in pregnant and UIC≥100 μg/l in non-pregnant women), and normal thyroid examination. We calculated multiples of the median (MoM) for TFTs to normalize the obtained data. The first trimester-specific reference intervals of serum TSH, FT4, and FT3 for pregnant women were 0.20–4.60 mIU/l, 9.0–18.02 pmol/l, and 3.40–5.64 pmol/l, respectively, while the corresponding figures for non-pregnant women were 0.59–5.60 mIU/l, 9.52–19.30 pmol/l, and 3.70–5.55 pmol/l, respectively. The first and 99th percentile MoM of TSH in pregnant women in their first-trimester was 0.026–4.61. The local normal reference ranges for the first trimester of pregnancy in central region of Iran were different from the ranges suggested by the ATA.
Watch and Wait in Rectal Cancer: Who’s In and Who’s Out?
Ahn, Daniel H. , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S

Mayo Clinic

Journal of Oncology Practice | March 12, 2019 | Volume: 15 | Issue: 3 | Pages: 133-134

10.1200/jop.19.00071 | PMID 30861365 Get It

NASH Is the Most Rapidly Growing Etiology for Acute‐on‐Chronic Liver Failure‐Related Hospitalization and Disease Burden in the United States: A Population‐Based Study
Axley, Page , Ahmed, Zunirah, Arora, Sumant, Haas, Allen , Kuo, Yong‐Fang, Kamath, Patrick S. , Singal, Ashwani K. , Singal, Ashwani K , Kuo, Yong‐Fang

Mayo Clinic

Liver Transplantation | March 12, 2019 | Volume: 25 | Issue: 5 | Pages: 695-705

10.1002/lt.25443 | PMID 30861321 Get It

Acute‐on‐chronic liver failure (ACLF) is characterized by multiple organ failure (OF) with high short‐term mortality. There is lack of population‐based data on trends on etiology specific ACLF related burden. National Inpatient Sample (2006‐2014) was queried using ICD‐09 codes for admissions with cirrhosis and ACLF (≥2 extrahepatic OF). Of 1,928,764 admissions for cirrhosis between 2006 and 2014, 112,174 (5.9%) had ACLF (4.5%, 1.2%, and 0.2% with ACLF 1, 2, and 3, respectively). The brain was the most common OF in 11.9%, followed by respiratory failure in 7.7%, cardiac failure in 6.3%, and renal failure in 5.6%. ACLF increased by 24% between 2006 and 2014 with a 63% increase in 179,104 patients with nonalcoholic steatohepatitis (NASH) cirrhosis (3.5% to 5.7%); a 28% increase in patients with 429,306 alcoholic cirrhosis (5.6% to 7.2%); a 25% increase in patients with 1,091,053 with other etiologies (5.2% to 6.5%); and no significant change in 229,301 patients with viral hepatitis (VH) (4.0% to 4.1%). In‐hospital mortality was higher among ACLF patients compared with patients without ACLF (44% versus 4.7%; P < 0.0001). Each NASH‐related ACLF patient compared with other etiologies had a longer mean length of stay (14 versus 12 days), was associated with higher median total charges (US $151,196 versus US $134,597), and had more frequent use of dialysis (45% versus 36%) and longterm care (32% versus 26%; P < 0.0001 for all). Results remained similar in a subgroup analysis after including half of admissions with cryptogenic cirrhosis as NASH. In conclusion, NASH cirrhosis is the most rapidly growing indication for ACLF‐related hospitalization and use of hospital resources. In the setting of improved treatment options for chronic hepatitis, the health care burden of chronic viral‐related liver disease remains stable. Population‐based strategies are needed to reduce the health care burden of cirrhosis, particularly related to NASH.
Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry
Gili, Sebastiano , Cammann, Victoria L. , Schlossbauer, Susanne Anna, Kato, Ken , Vece, Davide Di , Jurisic, Stjepan , Micek, Jozef, Obeid, Slayman , Bacchi, Beatrice , Szawan, Konrad A. , Famos, F , Sarcon, Annahita, Levinson, Rena A. , Ding, Katharina J., Bossone, Eduardo , Citro, Rodolfo , Franke, Jennifer , Napp, L. Christian , Münzel, Thomas , Knorr, Maike, Heiner, Susanne, Katus, Hugo A. , Burgdorf, Christof , Tschöpe, Carsten , Pieske, Burkert , Rajan, Lawrence, Michels, Guido, Pfister, Roman , Cuneo, Alessandro , Jacobshagen, Claudius, Karakas, Mahir , Köenig, Wolfgang , Rottbauer, Wolfgang , Said, Samir M., Banning, Adrian , Cuculi, Florim , Kobza, Richard , Fischer, Thomas, Vasankari, Tuija , Airaksinen, Juhani , Opolski, Grzegorz , Dworakowski, Rafał , MacCarthy, Philip , Osswald, Stefan , Galiuto, Leonarda , Dichtl, Wolfgang , Empen, Klaus , Felix, Stephan B. , Delmas, Clément , El‐Battrawy, Ibrahim , Akın, İbrahim , Borggrefe, Martin , Gilyarova, Ekaterina, Gilyarov, Mikhail , Horowitz, John D. , Kozel, Martin , Widimský, Petr , Winchester, David E. , Ukena, Christian , Wischnewsky, Manfred , Prasad, Abhiram , Böhm, Michael , Lüscher, Thomas F. , Ghadri, Jelena R. , Templin, Christian , Gilyarov, Mikhail , Bossone, Eduardo , Citro, Rodolfo , El-Battrawy, Ibrahim , Prasad, Abhiram , Tschöpe, Carsten , Koenig, Wolfgang , Banning, Adrian , Kobza, Richard , Gilyarov, Mikhail , Ukena, Christian , D’Ascenzo, Fabrizio , Seifert, Burkhardt , Lenoir, Olivia , Jaguszewski, Miłosz , Noutsias, Michel , Schunkert, Heribert , Thiele, Hölger , Bauersachs, Johann , Hasenfuß, Gerd , Braun-Dullaeus, Ruediger Christian , Kaiser, Christoph A. , Crea, Filippo , Lairez, Olivier , Shilova, Alexandra S. , Toušek, Petr , Gaïta, Fiorenzo , Mario, Carlo Di , Bax, Jeroen J. , Ruschitzka, Frank T.

Mayo Clinic

European Heart Journal | March 12, 2019 | Volume: 40 | Issue: 26 | Pages: 2142-2151

10.1093/eurheartj/ehz170 | PMID 31098611 Get It

Abstract Aims We aimed to evaluate the frequency, clinical features, and prognostic implications of cardiac arrest (CA) in takotsubo syndrome (TTS). Methods and results We reviewed the records of patients with CA and known heart rhythm from the International Takotsubo Registry. The main outcomes were 60-day and 5-year mortality. In addition, predictors of mortality and predictors of CA during the acute TTS phase were assessed. Of 2098 patients, 103 patients with CA and known heart rhythm during CA were included. Compared with patients without CA, CA patients were more likely to be younger, male, and have apical TTS, atrial fibrillation (AF), neurologic comorbidities, physical triggers, and longer corrected QT-interval and lower left ventricular ejection fraction on admission. In all, 57.1% of patients with CA at admission had ventricular fibrillation/tachycardia, while 73.7% of patients with CA in the acute phase had asystole/pulseless electrical activity. Patients with CA showed higher 60-day (40.3% vs. 4.0%, P &lt; 0.001) and 5-year mortality (68.9% vs. 16.7%, P &lt; 0.001) than patients without CA. T-wave inversion and intracranial haemorrhage were independently associated with higher 60-day mortality after CA, whereas female gender was associated with lower 60-day mortality. In the acute phase, CA occurred less frequently in females and more frequently in patients with AF, ST-segment elevation, and higher C-reactive protein on admission. Conclusions Cardiac arrest is relatively frequent in TTS and is associated with higher short- and long-term mortality. Clinical and electrocardiographic parameters independently predicted mortality after CA.
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis
Isaac, Gaëlle, Vries, Elisabeth G.E. de , Bogaerts, Jan , Chen, Alice P. , Dancey, Janet, Ford, Robert, Gwyther, Stephen J., Hoekstra, Otto S. , Huang, Erich P. , Liu, Yan , Mandrekar, Sumithra J. , Schwartz, Lawrence H., Shankar, Lalitha , Therasse, Patrick, Group, on behalf of the RECIST Working, de Vries, Elisabeth G E , Litière, Saskia , Lin, Nancy U. , Seymour, Lesley , Group, on behalf of the RECIST Working

Mayo Clinic

Journal of Clinical Oncology | March 12, 2019 | Volume: 37 | Issue: 13 | Pages: 1102-1110

10.1200/jco.18.01100 | PMID 30860949 Get It

PURPOSE The mode of action of targeted cancer agents (TCAs) differs from classic chemotherapy, which leads to concerns about the role of RECIST in evaluating tumor response in trials with TCAs. We investigated the performance of RECIST using a pooled database from 50 clinical trials with at least one TCA. METHODS We examined the impact of the number of target lesions (TLs) on within-patient variability of tumor response. The prognostic effect of TL response (at 12 weeks or on study on the basis of a maximum five TLs) on survival was studied through landmark and time-dependent Cox models adjusted for baseline tumor load, occurrence of new lesions, or unequivocal progression of nontarget disease. RESULTS Data were obtained from 23,259 patients with cancer (36% lung, 28% colorectal, 11% breast, and 25% other); 15,620 received TCAs, predominantly transduction or angiogenesis inhibitors, as a single agent (37%), combined with other TCAs (7%), or as chemotherapy (56%); 28% received chemotherapy only; and 5% received best supportive care or placebo. A total of 17,222 patients contributed to the analyses. Within-patient variability decreased with increasing number of TLs, similarly for TCAs (with/without chemotherapy) and chemotherapy only. Mixed responses occurred proportionally in all treatment classes. Landmark analyses showed an ordinal relationship between percentage change from baseline to 12 weeks and overall survival, and demonstrated a clear distinction between tumor shrinkage and progressive disease according to RECIST. Time-dependent analysis showed no marked improvement in the ability to predict survival on the basis of TL tumor growth compared with nontarget progression or new lesion occurrence, regardless of treatment. Similar results were seen for major tumor types and different classes of TCAs. CONCLUSION This work reinforces that RECIST version 1.1 perform well for response assessment of TCAs.